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Demethoxycurcumin (DMC; a curcumin-related demethoxy compound) has been recently shown to display antioxidant and
antitumoractivities.Ithasalsoproducedapotentchemopreventiveactionagainstcancer.Inthepresentstudy,theantiproliferation
(using the MTT assay, DMC was found to have cytotoxic activities against GBM 8401 cell with IC50 values at 22.71μM) and
induced apoptosis eﬀects of DMC have been investigated in human brain malignant glioma GBM 8401 cells. We have studied the
mitochondrial membrane potential (MMP), DNA fragmentation, caspase activation, and NF-κB transcriptional factor activity.
By these approaches, our results indicated that DMC has produced an inhibition of cell proliferation as well as the activation of
apoptosis in GBM 8401 cells. Both eﬀects were observed to increase in proportion with the dosage of DMC treatment, and the
apoptosis was induced by DMC in human brain malignant glioma GBM 8401 cells via mitochondria- and caspase-dependent
pathways.
1.Introduction
Turmeric (curcuminoids) is contained in curry (powder).
It has been used extensively in Asian countries and also in
traditional medicine [1]. Interest in this herb has grown
in recent years based on its reported putative beneﬁcial
pharmacological eﬀects, which include antioxidant, anti-
inﬂammatory [2, 3], and cancer-preventive properties [4, 5].
In addition to the actions of inhibiting cell proliferation and
increasing apoptosis [6–8], other mechanisms have also
been proposed to rationalize the anticarcinogenic eﬀect
of curcuminoids (curcumin and its related demethoxy
compounds: demethoxycurcumin (MW: 338.35g/mol,
Figure 1(a)) and bisdemethoxycurcumin (bDMC)), such
as the anti-inﬂammatory and antioxidant activities, the
induction of phase-II detoxiﬁcation enzymes, the inhibition
of cyclooxygenase 2 (COX-2), the eﬀe c to nA P - 1a n d
NFκB transcription factors, the inhibition of matrix
metalloproteinase (MMP) [9, 10], and the eﬀect on protein
kinases, others [11, 12].
A report showed that brain cancer is the eighteenth most
common malignancy cancer in Taiwan [13]. However, the
therapy for brain cancer is still not clear. One of the best
strategies for tumor suppression is to induce the apoptosis
pathway (caspase-dependent and -independent) in cancer
cells [14].Thecaspase-dependentpathwayinvolvesthedeath
receptor and then promotes the activations of caspase 3, 8,
and 9 [15]. The caspase-independent pathway is involved in
mitochondriadamage[16].Manystudieshavedemonstrated
that chemotherapy drugs synthesized from plants repress
tumor growth through the induction of apoptosis [17, 18].
Furthermore, other studies have linked chemoprevention
and chemotherapy to the prevention of the downregulation
of gap junctional intercellular communication by tumor2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Demethoxycurcumin (DMC) mediates the survival of GBM 8401 cells and thus inhibits their proliferation. (a) In vitro study
was initiated by treating each of the GBM 8401 cells to increasing doses of DMC (0, 12.5, 25, 50 and 100μM) for 24 or 48 hours. The
survival of these DMC-treated cancer cells was then measured by MTT method. Results were expressed as a percentage of control, which was
considered as 100%. All data were reported as the means (±SEM) of at least three separate experiments. Statistical analysis was via t-test,
with the signiﬁcant diﬀerences determined at the level of ∗P<0.05 versus control group (DMC 0μM). (b) The morphology of the human
GBM 8401 cells after the treatment with DMC (25μM) for 4 and 24 hours changed with the cells being distorted and suspended in the
medium.
promoters or the restoration of cell-cell communication in
cancercells[19].Becausemodulationofgapjunctionalinter-
cellular communication by epigenetic agents plays a major
role in homeostatic regulation of both stem and progenitor
cells in normal tissues, the modulation of this biological
process by both endogenous and endogenous chemicals
should be incorporated as an end point to monitor for po-
tential toxicities or chemopreventive attributes [20]. In ad-
dition, apoptosis has also been linked to the upregulation of
gap junction function [21, 22].
Glioblastomas (GBMs) are highly lethal primary brain
tumors, are grade IV gliomas, and appear to harbor therapy-
resistant cancer stem cells (CSCs) that are the major cause
of recurrence [23]. Human brain glioblastoma multiforms
[24, 25] or malignant glioma [26] GBM 8401 cells were
isolated and established from a Chinese female patient with
brain glioblastoma multiforme (GBM) [27]. These are tu-
morigenic in athymic nude mice [28]. Recent studies have
suggested that GBMs contain a subpopulation of tumor cells
that displays stem cell characteristics and could therefore
be responsible for in vivo tumor growth [29].Therefore, we
chose the GBM 8401 cells as a human brain glioblastoma
model to analyze the antitumor activity of DMC.
In this paper, studies have been initiated to investigate
whether DMC could contribute to the antiproliferation and
apoptosis of human brain malignant glioma GBM 8401 cells.
We expect that all of these experiments could provide a sci-
entiﬁcbasisandtechnologicalsupportforbrainglioblastoma
therapy.
2.MaterialsandMethods
2.1. Cells Culture. The human brain malignant glioma GBM
8401 cells were purchased from the Food Industry Research
and Development Institute (Hsinchu, Taiwan). These were
maintained on culture dishes, in RPMI 1640 supplemented
with 10% (v/v) FBS. The cells were cultured in an atmo-
sphere containing 5% CO2 at 37◦C incubator.
2.2. Cell Proliferation Assay. The cells were seeded into 96-
well culture plates at 5000 cells/well. Diﬀerent cell wells were
treated with 0, 12.5, 25, 50, and 100μMD M C ,r e s p e c t i v e l y ,
for 1 or 2 days. MTT dye (1mg/mL) was added to each well
for the extra 4 hours after treatment. The reaction was
stopped by the addition of DMSO, and optical density was
measured at 540nm on a multiwell plate reader (Powerwave
XS, Biotek). Background absorbance of the medium in the
absence of cells was subtracted. All samples were assayed in
triplicate, and the mean for each experiment was calculated.
Results were expressed as a percentage of control, which was
considered as 100%. Each assay was carried out in triplicateEvidence-Based Complementary and Alternative Medicine 3
and the results were expressed as the mean (±SEM). The
change in cell morphology was determined microscopically
by Olympus CKX41.
2.3. Mitochondrial Membrane Potential (MMP). The GBM
8401 cells were ﬁrst seeded in 24- or 6-well plates (Orange
Scientiﬁc. E.U.). Following the treatment with DMC for
4 hours, Rhodamine 123 (10μg/mL, Sigma-Aldrich, St.
Louis, MO, USA) and JC-1 (25μM) were added to the
culture medium (500μL/well) and then incubated (37◦C,
20min) for mitochondria staining. After washing twice with
a warm PBS, the cells were ﬁxed with 2% paraformaldehyde,
inspected by a ﬂuorescence microscopy (Olympus CKX41
and U-RFLT 50), and the RFU (relative ﬂuorescence unit)
was detected by the BioTek FLx800 TBI. For Rhodamine 123,
the wavelength settings were 504nm and 534nm. Each assay
was carried out in triplicate, and the results were expressed
as the mean (±SEM) of RFU and reported as the percentage
of the RFU for the control group (DMC 0μM). For JC-1,
the quantiﬁcation by ﬂow cytometry (BD FACScalibur, BD,
USA) and mitochondria containing red JC-1 aggregates in
healthy cells were detectable in the FL2 channel, and green
JC-1 monomers in apoptotic cells were detectable in the FL1
channel.
2.4. Cell Cycle Analysis. The method for cell cycle analysis
used propidium iodide (PI), that is, using the ﬂuorescent
nucleic acid dye PI to identify the proportion of cells that are
inoneofthethreeinterphasestagesofthecellcycle.Thecells
were treated with 0, 12.5, 25, and 50μMD M Cf o r2 4h o u r s ,
thenharvestedandﬁxedin1mLcold70%ethanolforatleast
8h o u r sa t−20◦C. DNA was stained in PI/RNaseA solution,
and the cell cycle (at least 10,000 single cells) was detected by
ﬂow cytometry (FACSCalibur, BD, USA). Data was analyzed
by WinMDI 2.8 free software (BD, USA).
2.5.MeasurementofApoptosis. TheGBM8401cellswereﬁrst
seeded in 6-well plates (Orange Scientiﬁc. E.U.). Following
thetreatmentwithDMCfor4hours,thecellswereharvested
after the incubation period and washed in cold phosphate-
buﬀered saline (PBS). A 1X annexin-binding buﬀer (BD
Pharmingen, BD, USA) and 100μg/mL working solution of
propidium iodide (PI) (Sigma, USA) were prepared. The
washed cells were recentrifuged (the supernatant discarded)
and resuspended in 1X annexin-binding buﬀer. Five μLo f
FITC annexin V (BD Pharmingen, BD, USA) and 1μL of the
100μg/mL PI working solution were added to each 100μL
of cell suspension, and the cells were incubated at room
temperature for 15 minutes. After the incubation period,
the stained cells were analyzed by ﬂow cytometry, and the
ﬂuorescence emission measurement showed only low levels,
apoptotic cells showed green ﬂuorescence and dead cells
s h o w e db o t hr e da n dg r e e nﬂ u o r e s c e n c e .
2.6.DNAFragmentationAssay. TheDNAfragmentationwas
detected by ApoAlert DNA fragmentation assay kit (Clon-
tech, USA). The assay is based on terminal-deoxynucleot-
idyl-transferase-(TdT-) mediated dUTP nick-end-labeling
(TUNEL). TdT catalyzes incorporation of ﬂuorescein-dUTP
at the free 3 -hydroxyl ends of fragmented DNA. The cells
were treated with DMC for 16 hours, and the ﬂuorescein-
labeled DNA was detected via confocal microscopy system
(CARV II, BD, USA) and ﬂow cytometry (FACSCalibur, BD,
USA); data were analyzed by WinMDI 2.8 free software (BD,
USA).
2.7. Western Blot Assay. A total of 30–50μg proteins were
separated by SDS-PAGE (10–12% SDS-polyacrylamide gel
electrophoresis) and transferred to PVDF membranes (Mil-
lipore, USA) in a tank blotter (in 25mM Tris/0.192M gly-
cine, pH 8.3/20% methanol) at 30 voltage overnight. The
membranes were blocked with blocking buﬀer (Odyssey,
USA) overnight and incubated with anti-β-actin (Sigma-
Aldrich, St. Louis, MO, USA) and anti-caspase 3 (Santa Cruz
BioTechnology, USA) antibody for 1.5∼2 hours. The blots
were washed with Tris-HCl (pH 8.0/150mM NaCl/0.05%
Tween-20) for 3 × 10 minutes and incubated with sec-
ond antibody (anti-rabbit or anti-mouse immunoglobulins)
(IRDye Li-COR, USA) at 1/20000 dilution for 30 minutes.
The antigen (β-actin and caspase 3) was then visualized by
Odyssey near-infrared imaging system (Odyssey LI-COR,
USA) and data analyzed by Odyssey 2.1 software.
2.8. Caspase Activity Assay. T h ec a s p a s e( 2 ,3 ,8 ,a n d9 )a c -
tivity was assessed by the ApoAlert Caspase assay plates
(Clontech,USA).ThecellsweretreatedwithDMCof0,12.5,
25, and 50μM with or without caspase-speciﬁc inhibitor
for 8 hours. The caspase activity was detected by ApoAlert
Caspase assay plates and inspected by the BioTek FLx800 TBI
reader (BioTek, USA). The plates contained the ﬂuorogenic
substratesandinhibitorsspeciﬁcfordiﬀerentcaspases.These
substrates were covalently linked to their respectively acti-
vated caspases. The substrates were covalently linked to
the ﬂuorogenic dye 7-amino-4-methyl coumarin (AMC).
Peptide-bound AMC excites in the UV range (380nm) and
emits at 460nm. The AMC was normalized by total protein;
each assay was carried out in triplicate, and the results were
expressed as the mean (±SEM).
2.9. NF-κB Transcription Factor Assay. The NF-κB transcrip-
tion factor was assessed by the NoShift II NF-κBt r a n -
scription factor assay kit (NOvagen, USA) and confocal
microscopy. The cells were treated with 0, 12.5, 25, and
50μM DMC for 6 hours. After treatment, the cell nuclear
fraction was isolated by NucBuster Protein Extraction Kit
(NOvagen, USA). The NF-κB transcription factor measures
light intensity by microplate luminometer (BioTek FLx800
TBI reader BioTek, USA). The relative light units (RLUs)
were normalized by total protein; each assay was carried
out in triplicate, and the results were expressed as the mean
(±SEM). Confocal microscopy was performed as described
previously. Brieﬂy, the GBM8401 cells (2 × 106 cells) were
treated with 0 and 25μM DMC for 6 hours and were ﬁxed
on coverslips. After treatment, samples were incubated with
rabbit anti-human p50 antibody (SC-8414 PE, Santa Cruz
Biotechnology) for 30 minutes then washed with PBS. The
cells were mounted onto microscope slides using mounting
medium containing DAPI.4 Evidence-Based Complementary and Alternative Medicine
2.10. Statistical Analysis. All data were reported as the means
(±SEM) of at least three separate experiments. A t-test
or one-way ANOVA with post hoc test was employed for
statistical analysis, with signiﬁcant diﬀerences determined as
P<0.05.
3. Results
3.1. DMC Inhibits the Proliferation of GBM 8401 Cells. It
is hypothesized that DMC could mediate the survival of
human brain malignant glioma GBM 8401 cells and thus
inhibit their proliferation. To explore this antitumor activity
of DMC against the GBM 8401 cells, an in vitro study was
initiated by treating each sample of the GBM 8401 cells
to increasing doses of DMC (0, 12.5, 25, 50, and 100μM)
for 24 or 48 hours. The proliferation of these DMC-treated
cancer cells was then measured by MTT method. The results
summarized in Figure 1(a) indicate that the survival and
proliferation of GBM 8401 cells were decreased by DMC
treatment in a dose-dependent reduction manner. The IC50
of DMC in the GBM 8401 cancer cells was determined,
respectively, to be 22.71μM; y = 88.413e − 0.0251x, R2 =
0.921 (P<0.05 versus DMC 0μM). Moreover, DMC was
noted to induce a morphological change in the GBM 8401
cells. In Figure 1(b), microscopic examination shows that,
following the exposure to DMC (25μM) for 4 to 24 hours,
the cancer cells have displayed a remarkable change in their
morphology. DMC induced the death of cancer cells, which
formed a suspension in the medium.
3.2. DMC Reduces the MMP in GBM 8401 Cells. To explore
the possible eﬀect of DMC on the MMP in the GBM 8401
cells, Rhodamine 123 was used to determine the MMP
in the DMC-treated cancer cells. The results compared in
Figure 2(a) indicate that the MMP of the GBM 8401 cells
has been reduced after treatment with DMC. The results
summarized in Figure 2(b) indicate that the intensity of
ﬂuorescence, as determined by the BioTek FLx800 TBI
ﬂuorescence reader, decreases as the DMC dose increases.
The observations imply that the reduction of MMP in
the GBM 8401 cells depends on the dosage of DMC used
(P<0.05 versus DMC 0μM). The loss of mitochondrial
membrane potential is a hallmark for apoptosis. It is an
early event coinciding with caspase activation. In non-
apoptotic cells, JC-1 exists as a monomer in the cytosol
(green) and accumulates as aggregates in the mitochondria,
which appear red. In apoptotic and necrotic cells, JC-1
exists in monomeric form and stains the cytosol green.
Figure 2(c) shows typical FL-1/FL-2 dot plots for JC-1
staining GBM8401 cells with and without apoptosis. DMC-
free GBM8401 cells without apoptosis had red ﬂuorescing
J-aggregates. The green ﬂuorescing monomers shown in
the lower region indicate apoptotic cell lines (DMC 12.5,
25, and 50μM treatment). By ﬂow cytometry assays, we
observed that the cells exposed to DMC exhibited a dose-
dependent decrease in JC-1 staining compared to the
untreated control cells. This indicated that there was a
loss of mitochondrial membrane potential in DMC-treated
cells, which approached the loss of potential observed after
treating the cells. As clearly observed from the ﬁgure, DMC
induced signiﬁcant depolarization at 25 and 50μMD M C
concentrations wherein there was a 34- and 50-fold reduc-
tion in the ratio of red-green ﬂuorescence intensity. Taken
together, all these results suggest that DMC exhibited a
potent antineoplastic eﬀect in GBM 8401 cells through loss
of mitochondrial membrane potential, ultimately leading to
apoptosis.
3.3. DMC Treatment Induces Accumulated Sub-G0/G1 in
GBM 8401 Cells. Cell-cycle distribution of DMC-treated
GBM 8401 cells was analyzed by ﬂow cytometry, aiming to
determinewhethertheinhibitoryeﬀectwasduetoapoptosis.
Before being processed and analyzed, the cells were exposed
to DMC for a total of 24 hours. As shown in Figure 3(a),
the cells exposed to DMC showed increase in the number
of cells in the sub-G0/G1 phase, as compared with that of
the untreated cells. The observations could imply that the
GBM 8401 cells have undergone apoptosis. We found that
treatment of DMC resulted in increase of cell populations
in sub-G1 (Figure 3(b))( P<0.05 versus DMC 0μM) and
a concomitant decrease of cell numbers at other phases
(Figure 3(a)).
3.4. Induction of Apoptosis-Dependent Cell Death by DMC in
GBM 8401 Cells. To further elucidate the anticancer mech-
anism of DMC in GBM 8401 cells, we performed apoptosis
studies. After treating the cells with diﬀerent doses of DMC,
the percentage of apoptotic cells were assessed by Annexin
V-FITC and propidium iodide staining, followed by ﬂow
cytometric analysis (Figure 3(c)). The dot plot of Annexin
V-FITC ﬂuorescence versus PI ﬂuorescence also indicated a
signiﬁcant increase of the percentage of apoptotic cells that
weretreatedbyDMC.Itwasobservedthat,atconcentrations
o f1 2 . 5t o5 0μM DMC, there was a signiﬁcant increase in the
percentage of cells undergoing apoptosis.
3.5. DMC Induced DNA Fragmentation in GBM 8401 Cells.
Cells undergoing apoptosis will lose part of their DNA (due
to the DNA fragmentation in later apoptosis). The visibility
of “sub-G1” peaks by ﬂow cytometry might be an index of
the formation of characteristic DNA ladders [30].I ti sh y -
pothesized that DMC could induce apoptosis of GBM 8401
cells via the DNA fragmentation. To explore this eﬀect of
DMC against the GBM 8401 cells, an in vitro study was
initiated by treating each of the GBM 8401 cell samples
with 25μM DMC for 16 hours. After treatment, the DNA
fragmentation was detected by ﬂuorescein-labeled DNA via
confocal microscopy system and ﬂow cytometry. The DNA
fragmentation is illustrated in Figure 4(a), with apoptotic
cells exhibiting nuclear green ﬂuorescence. All cells stained
with propidium iodide exhibit red cytoplasmic ﬂuorescence.
TheresultsindicatedthatDMCinducedDNAfragmentation
in GBM 8401 cells. The quantiﬁcation of DNA fragmenta-
tion was measured by the ﬂuorescence intensities by ﬂow
cytometry (Figure 4(b)), showing that DNA fragmentation
levels were signiﬁcantly increased in cells incubated with
DMC. Taken together, the observations imply that DMCEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Reduction of the mitochondrial membrane potential (MMP) in the GBM 8401 cells by DMC, which was determined by
Rhodamine 123 and JC-1 staining and detected by ﬂuorescence microscopy, ﬂuorescence reader, and ﬂow cytometry: (a) MMP is shown to
be signiﬁcantly reduced in the GBM 8401 cells treated with DMC (12.5, 25, and 50,μM) by Rhodamine 123 staining, and the same eﬀect
was also demonstrated by JC-1 staining (c). (b) Using BioTek FLx800 TBI ﬂuorescence reader, the intensity of ﬂuorescence was determined
and found to decline (presented as the percentage of the controls) as the concentration of DMC used to treat the GBM 8401 cells increased.
All the data shown are the mean (±SEM) of at least three independent experiments. The symbol (∗) on each group of bars denotes that
diﬀerence from the treatment with 0μM DMC is statistically signiﬁcant at P<0.05.6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Eﬀects of DMC on cell cycle progression/distribution and apoptosis in GBM 8401 cells. (a) cell cycle distribution and (b) cell cycle
analysis of sub-G1 in GBM 8401 cells after culturing with DMC for 24h. Treatment with DMSO (0.1%) was used as the control. All data
were reported as the means (±SEM) of at least three separate experiments. Statistical analysis used the t-test, with the signiﬁcant diﬀerences
determined at the level of ∗P<0.05 versus 0μM control group. (c) DMC induced the increase of both early apoptosis (Annexin V positive,
PI negative) and late apoptosis/necrosis (Annexin V/PI double positive) in GBM 8401 cells for 4h of incubation.
signiﬁcantly induced the DNA fragmentation of GBM 8401
cells.
3.6. Apoptosis Induction by DMC in GBM 8401 Cells via
Caspase 3, 8, and 9 Activation. Immunoblotting of cellular
proteins from GBM 8401 cells treated with DMC showed de-
crease of pro-caspase-3 after DMC incubation (Figure 5(a)).
Quantiﬁcation of pro-caspase-3, done by measuring the rel-
ative band intensities, showed that pro-caspase-3 levels
were signiﬁcantly lower in cells incubated with DMC
(Figure 5(b)). The results indicated that DMC induced
caspase 3 activity via cleaved pro-caspase-3 and apoptosis
after DMC incubation. As shown in Figure 5(c), the DMC
elevated the caspase 3, 8, and 9 activities in GBM 8401 cells
that had been decreased with caspase-speciﬁc inhibitors. The
results summarized in Figure 5 indicate that the increased
levelsofcaspaseactivitymayplayanimportantroleinDMC-
induced apoptosis in GBM 8401 cells.
3.7. DMC Inhibits Nuclear NF-κB Transcription Factor Activ-
ity in GBM 8401 Cells. To explore the potential role where
DMC inhibits nuclear NF-κB transcription factor activity of
GBM 8401 cells, the NoShift II transcription factor assay kit
has been used to identify the activity of NF-κB transcriptionEvidence-Based Complementary and Alternative Medicine 7
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Figure 4: Demethoxycurcumin induced DNA fragmentation in GBM 8401 cells. (a) The cells were treated with DMC for 16 hours. The
DNA fragmentation was detected by ﬂuorescein-labeled DNA via confocal microscopy system. The apoptotic cells exhibit nuclear green
ﬂuorescence. All cells stained with propidium iodide exhibit red cytoplasmic ﬂuorescence. (b) Quantiﬁcation of DNA fragmentation by
measuring the ﬂuorescence intensities by ﬂow cytometry. The data showed that DNA fragmentation levels were signiﬁcantly elevated in cells
incubated with DMC incubation for 16 hours. All data were reported as the means (±SEM) of at least three separate experiments. Statistical
analysis used t-test, with the signiﬁcant diﬀerences determined at the level of ∗P<0.05 versus 0μM control group.
factor in the GBM 8401cells after the 6 hours of exposure to
DMC followed by examination with microplate luminome-
ter. The results summarized in Figure 6(a) indicate that the
NF-κB transcription factor activity of GBM 8401 cells has
been repressed through increasing the dose of DMC added
into the cell cultures. The results in Figure 6(b) indicate that
less NF-κB subunit p50/52 was observed in the nuclei of
GBM8401 cells treated with DMC 25μM than in the nuclei
of DMC-free GBM8401 cells. The results could imply that
theGBM8401cellshavehadtheiractivityofNF-κBrepressed
in relation to increased dosage of DMC added into the cell
cultures.
4. Discussion
Dietary constituents may display promising chemopreven-
tive and chemotherapeutic potential and thus ameliorate the
side eﬀects associated with conventional chemotherapy [4].
Recently, more attention has been focused on comple-
mentary and alternative medicine (CAM) as an alternative
therapeutic modality for treatment of cancer patients. Cell
cycle progression and apoptosis are two pivotal signaling
mechanisms used to maintain normal condition in healthy
tissues. As a dietary supplement or spicing agent, curcum-
inoids are used worldwide and their many uses have led
to studies aimed at elucidating the mechanism of their
activities, in particular the anticancer activity [5]. Most
anticancer agents and DNA damaging agents arrest the cell
cycle at the G0/G1 or G2/M phase and then induce cell
apoptosis. Our data from ﬂow cytometry analysis showed
that the cell cycle increased in the sub-G1 phase in GBM
8401 cells incubated with DMC. These results demonstrate
an inhibitory role for DMC in GBM 8401 cells, which is
associated with induction of apoptosis.
The results collected in this series of studies with the
cell lines of human brain malignant glioma cells have pro-
vided experimental evidence to indicate that DMC could
irreversibly induce apoptosis of these cancer cells. These
culminate with several phase I human trials that have shown
curcuminoids to be well tolerated [31]. The most com-
mon cell death mode on curcuminoids treatment seems to
be apoptosis [32]. Apoptosis can be triggered by a large
variety of diﬀerent stimuli. To date, two major intracellular
apoptosis signaling pathways have been identiﬁed: intrinsic
and extrinsic. The intrinsic pathway involves an increase of
outer mitochondrial membrane permeability. The extrinsic
pathway involves ligation of death (Fas) receptor, resulting
in the recruitment of the adaptor protein FADD through
interaction between the death domains of both molecules
[33]. In both pathways, the stress-mediated apoptosis is
often triggered by mitochondrial function loss. Accordingly,
this functional loss in DMC-mediated apoptosis was also
explored in MTT viability and MMP assay. Therefore, the
apoptosisinducedbyDMCwasconsideredtobethroughthe
intrinsic pathway related to mitochondrial dysfunction.
Caspases, a family of cysteinyl aspartate-speciﬁc prote-
ases,playanessentialroleintheregulationandtheexecution
of apoptotic cell death. Multiple apoptotic stimuli trigger the
activation of proteases called caspases; caspases are constitu-
tively expressed in almost all cell types as inactive proen-
zymes that are processed and activated in response to a vari-
ety of proapoptotic stimuli [34]. All caspases are produced
in cells as inactive zymogens and require a proteolytic cleav-
age and then convert to active form during apoptosis. Cas-
pases are typically divided into three major groups, depend-
ing on the structure of their prodomain and their function
[35]. The ﬁrst is inﬂammatory caspases (1, 4, 5, 11, 12,
and 14), the second group initiator-of-apoptosis caspases8 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Apoptosis induction by DMC in GBM 8401 cells via caspase 3, 8, and 9 activations. DMC activated pro-caspase-3 degradation
in GBM 8401 cells. The cells were treated with DMC (0, 12.5, 25, and 50μM), and then (a) Western blot analysis was performed for pro-
and cleaved- caspase-3. (b) Quantiﬁcation of band intensities by Li-COR near-infrared imaging system. All data were reported as the means
(±SEM) of at least three separate experiments. Statistical analysis used the t-test, with the signiﬁcant diﬀerences determined at the level of
∗P<0.05versus0μMcontrolgroup.(c)Thecaspase2,3,8,and9activitywasanalyzedbyApoAlertCaspaseassayplates.TheDMCinduced
the caspase activity of GBM 8401 cells. All data were reported as the means (±SEM) of at least three separate experiments. Statistical analysis
w a sa sc i t e da b o v e .
(2,8,and9),andthethirdeﬀectorcaspases(3,6,and7)[36].
Caspase 2 was initially described as a neuronally expressed
caspase that was downregulated during the course of brain
development [37]. Two forms of caspase 2 were found—a
short antiapoptotic form and a longer proapoptotic form
[38]. It can be demonstrated that other caspases can replace
caspase 2 as the executioner if inhibitors and facilitators of
apoptosis are appropriately regulated. It is also clear that
there exist many cell death paradigms where the executioner
is not caspase 2, but rather caspase 3 or 7 [39]. Caspase 3
is the most extensively studied apoptotic protein and is a
key eﬀector caspase in the apoptosis pathway, amplifying the
signal from initiator caspases (such as caspase 8) and signify-
ing full commitment to cellular disassembly [40]. Caspase 8
is a key enzyme in the apoptosis pathway. Caspase 8 contains
two N-terminal region death eﬀector domains which are re-
moved to activate the enzyme along with cleavage into the
two subunits [41]. These subunits then form the active pro-
tease which is capable of cleaving caspase 3, 6, and 7, which
correspondingly initiate the death cascade and ﬁnally in-
duce apoptosis. Therefore, the DMC-induced apoptosis was
mediated throughactivation of caspasecascade(3,8,and 9).Evidence-Based Complementary and Alternative Medicine 9
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Figure 6: DMC inhibits nuclear NF-κB transcription factor activity
in GBM 8401 cells. (a) The NoShift II transcription factor assay
kit was used to identify the activity of NF-κB transcription factor
in the cells after exposure to DMC followed by examination with
microplate luminometer. (b) Diminished NF-κB activity in DMC-
treated GBM8401 cells. The cells were examined for their NF-κB
activity 6 hours after DMC stimulation by confocal microscopy
of NF-κB subunit p50/52 localization. The cells were stained for
p50/52 (red). DAPI (blue) indicates nucleus, where an active form
of NF-κB subunit p50/52 is found. All data were reported as the
means (±SEM) of at least three separate experiments. Statistical
analysis was as cited above.
Many studies have led to the discovery of two major
apoptotic nucleases, termed DNA fragmentation factor
(DFF) [42] or caspase-activated DNase (CAD) [43]a n d
endonuclease G. Both endonucleases attack chromatin to
yield 3-hydroxyl and 5-phosphate termini, ﬁrst creating
50 to 300kb cleavage products and then oligonucleosomal
fragmentation, but these nucleases show diﬀerent cellular
locations and are regulated in fundamentally diﬀerent ways.
Although activation of the executorial caspases seems to
be indispensable for realization of the apoptotic program,
several forms of cell demise have been shown to be caspase-
independent or even accelerated by caspase inhibitors [44].
The observations of this study have implied that DMC has
signiﬁcantly induced the DNA fragmentation of GBM 8401
cells.
Nuclear factor-κB( N F - κB) plays an important role in
cell proliferation and apoptosis by regulating the expression
of genes involved in these processes [45]. Active NF-κB
is most commonly composed of the heterodimer DNA-
binding subunits p50 and p65. It has recently been shown
that inactivation of p65 subunit of NF-κB leads to the
death through apoptosis of liver cells [46]. Similarly, it has
been shown in a wide range of cells that when NF-κB
has been inactivated by Iκ-Bα, cells were more sensitive
to TNF-α—induced apoptosis. Evidence exists for NF-
κB playing both anti- and proapoptosis roles [47]. The
release of NF-κB facilitates its translocation to the nucleus,
where it promotes cell survival by initiating transcription
of genes encoding stress-response enzymes, cell-adhesion
molecules, proinﬂammatory cytokines, and antiapoptotic
proteins [48]. The reducing levels of NF-κBm a yb ei n v o l v e d
in curcuminoid-induced apoptosis of GBM 8401 cells.
Curcuminoids, well-established dietary antioxidants, are
a safe natural food coloring additive with lipid-lowering po-
tency in vivo [49, 50] and anticarcinogenic [51, 52], hep-
atoprotective [53], and neuroprotective properties [54],
against heavy-metal-induced neurotoxicity and Alzheimer’s
disease [55, 56]. Curcuminoids have shown a variety of
biological activities for various human diseases in preclinical
setting. Thier poor oral bioavailability poses signiﬁcant
pharmacological barriers to thier clinical application. Lipo-
somal[57]ornanoemulsioncurcuminoids(NECs)[58]ma y
conducted the pharmacokinetics of curcuminoids in vivo
[59]. Purkayastha et al. show that a soluble formulation of
curcuminoids crosses the blood-brain barrier but does not
suppress normal brain cell viability. Furthermore, tail vein
injection, or more eﬀectively intracerebral injection through
a cannula, blocks brain tumor formation in mice [60]o rh a s
neuroprotective eﬀect on focal cerebral ischemic rats [61].
Taken together, in this work, the bioactivities of DMC
were studied. In particular, it could eﬀectively induce the
apoptosis and cell cycle sub-G1 and cell cycle arrest of GBM
8401 cells. The apoptosis induction was revealed to be
through activation of the caspase cascade. These results
indicate that DMC is deserving further study as a potential
chemotherapeutic drug.
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